Aurora Cannabis Buys UK Importer and Pharmacy to Control Patient Supply Chain

Aurora Cannabis has acquired two licensed British businesses (medical cannabis importer and wholesaler Internode Pharma Limited and pharmacy operator HAP Pharma Limited) for £2.1 million in cash, giving the Canadian producer direct control of the supply chain that carries its products from cultivation to UK patients, the company announced on August 19, 2026.

The two companies operate a licensed import and distribution facility and a virtual pharmacy out of Birmingham, England. Aurora bought 100% of the shares in both through a wholly-owned subsidiary, with the cash consideration contingent on certain conditions being satisfied after closing.

Aurora described the UK as one of the largest European medical cannabis markets, serving a population of roughly 70 million people, and said it expects the transaction to add to adjusted EBITDA in future quarters through operational efficiencies and reduced reliance on third-party distributors.

“The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market,” said Miguel Martin, Aurora’s Executive Chairman and Chief Executive Officer, in the company’s announcement.

Martin added that patient demand, acceptance of Aurora’s products and “increasingly prescriptive regulatory standards” make the UK an attractive market, and that owning the two licensed businesses gives Aurora “greater agility to more reliably serve UK patients.”

What the Two Licences Actually Give Aurora

The structure of the deal matters for anyone watching how medical cannabis actually reaches patients in Britain. The UK does not permit domestic commercial cultivation of cannabis-based medicines at meaningful scale, so the market runs on imports: product grown and manufactured overseas — Aurora operates GMP-certified production facilities in Canada and Germany — moves through licensed importers and wholesalers, then reaches patients through pharmacies dispensing against private prescriptions.

Internode Pharma holds an import and wholesale licence, the gate through which imported medical cannabis, including Aurora’s own product, enters legitimate UK distribution. HAP Pharma operates a virtual pharmacy, the dispensing end of the chain, where prescriptions are filled and delivered to patients. Until this acquisition, Aurora sold into that chain as an upstream supplier and depended on independent intermediaries to move and dispense its products. Owning both the importer and the pharmacy removes that dependence and gives the company visibility into, and control over, the final leg of delivery.

Aurora said it intends to apply its commercial, regulatory and operational expertise to streamline the combined operation and take market share, and that it will evaluate further investment in UK distribution capacity as patient demand grows.

The Deal Lands in the Middle of a Takeover Fight

The acquisition is Aurora’s first announced transaction since Curaleaf launched an unsolicited take-over bid for the company. Curaleaf formally commenced its offer on August 18, 2026, offering US$4.00 per Aurora share, a mix of Curaleaf stock and US$0.75 in cash, which Curaleaf said represented a 45% premium to Aurora’s unaffected share price. The offer remains open until December 1, 2026.

Aurora’s board responded the morning of August 19, 2026, urging shareholders to take no action until a special committee of independent directors delivers a formal recommendation, expected within 15 days. In that response, Aurora argued Curaleaf’s real objective is to acquire its “highly strategic EU-GMP facilities and leading medical cannabis platforms at the lowest price possible” — the same international medical infrastructure Aurora is now extending into the UK.

Curaleaf, for its part, has pointed to regulatory pressure in Aurora’s two largest markets, citing reduced Canadian medical cannabis reimbursement rates and the cancellation of German medical cannabis reimbursement, alongside what it called consecutive quarters of underperformance. Aurora’s answer, visible in its recent moves, has been to keep investing in exactly the European medical platform Curaleaf says is under strain. MyCannabis has covered Curaleaf’s bid for Aurora and Aurora’s instruction to shareholders to take no action.

A Bigger UK Push Across the Industry

Aurora’s vertical integration fits a broader pattern of international producers building direct routes into the UK medical market. Aurora’s most recent quarterly results showed international medical cannabis sales up 17%, and other operators are moving in the same direction: New Zealand’s Rua Bioscience signed its largest export agreement with a UK clinic in July 2026, and Dunbar Pharma recently shipped the first plant-derived dronabinol API to UK patients.

What distinguishes Aurora’s move is that it buys the regulatory infrastructure rather than contracting for it. The Companies operate a licensed import and distribution facility and a virtual pharmacy, giving Aurora direct ownership and control of the supply chain from cultivation through to delivery to patients. Aurora now holds both, at a purchase price below what many of its peers have paid for far less control.

The next dated milestone in Aurora’s wider situation arrives before any of this integration plays out: the company’s board must deliver its formal recommendation on the Curaleaf offer by early September 2026, and the offer itself runs until December 1, 2026.